Roche (VTX:ROG) has been given a CHF 300 target price by equities research analysts at Jefferies Group in a report issued on Friday. The brokerage currently has a “buy” rating on the healthcare company’s stock. Jefferies Group’s price objective points to a potential upside of 18.76% from the company’s current price.
ROG has been the topic of a number of other reports. Goldman Sachs Group set a CHF 325 price target on Roche and gave the stock a “buy” rating in a research note on Thursday, October 12th. Morgan Stanley set a CHF 260 price target on Roche and gave the stock a “neutral” rating in a research note on Friday, November 17th. Deutsche Bank set a CHF 264 price target on Roche and gave the stock a “neutral” rating in a research note on Tuesday, December 12th. JPMorgan Chase & Co. reaffirmed a “buy” rating and issued a price target on shares of Roche in a research note on Monday, October 16th. Finally, Liberum Capital set a CHF 279 price target on Roche and gave the stock a “buy” rating in a research note on Wednesday, November 22nd. Three investment analysts have rated the stock with a sell rating, eight have issued a hold rating and nine have given a buy rating to the company’s stock. The company has an average rating of “Hold” and a consensus price target of CHF 263.42.
Shares of Roche (VTX ROG) opened at CHF 252.60 on Friday. The stock has a market capitalization of $217,750.00 and a P/E ratio of 22.45. Roche has a 12 month low of CHF 226.10 and a 12 month high of CHF 273.
ILLEGAL ACTIVITY WARNING: This story was originally reported by Ticker Report and is owned by of Ticker Report. If you are accessing this story on another site, it was illegally stolen and republished in violation of U.S. & international copyright and trademark legislation. The original version of this story can be read at https://www.tickerreport.com/banking-finance/3126537/roche-rog-given-a-chf-300-price-target-by-jefferies-group-analysts.html.
Roche Holding AG (Roche) is a research-based healthcare company. The Company’s operating businesses are organized into two divisions: Pharmaceuticals and Diagnostics. The Pharmaceuticals Division consists of two business segments: Roche Pharmaceuticals and Chugai. The Diagnostics Division consists of four business areas: Diabetes Care, Molecular Diagnostics, Professional Diagnostics and Tissue Diagnostics.
Receive News & Ratings for Roche Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Roche and related companies with MarketBeat.com's FREE daily email newsletter.